drugset / Trial / NCT00713401

Safety Study of Tecadenoson to Treat Atrial Fibrillation

NCT00713401

Phase 2 Completed 21 enrolled Gilead Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic effects when given alone and in combination with beta-blocker (esmolol).

Timeline

Start
2008-02
Primary completion
2008-04
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Esmolol Other / unclassified 50 ug/kg
Subject Tecadenoson Small molecule 75 ug Intravenous
Subject Tecadenoson Small molecule 150 ug Intravenous
Subject Tecadenoson Small molecule 300 ug Intravenous

Indications